These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19658353)

  • 21. BRCA screening.
    Obstet Gynecol; 2008 May; 111(5):1205-6. PubMed ID: 18448758
    [No Abstract]   [Full Text] [Related]  

  • 22. The BRCA breast cancer patient: treat the tumor or the problem?
    Zippel D; Papa MZ
    J Surg Oncol; 2008 Jun; 97(7):561-2. PubMed ID: 18302144
    [No Abstract]   [Full Text] [Related]  

  • 23. [Systematic breast self-examination is not a useful screening procedure, except in hereditary or familial increased risk of breast cancer].
    Kaas R; Rutgers EJ
    Ned Tijdschr Geneeskd; 2008 Oct; 152(43):2317-8. PubMed ID: 19024059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Familial breast cancer and hereditary breast cancer].
    Masuoka H; Mikami T; Yamazaki K; Shimokawara I; Asaishi K
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():55-8. PubMed ID: 23350365
    [No Abstract]   [Full Text] [Related]  

  • 25. BRCA mutation frequency and penetrance: new data, old debate.
    Offit K
    J Natl Cancer Inst; 2006 Dec; 98(23):1675-7. PubMed ID: 17148764
    [No Abstract]   [Full Text] [Related]  

  • 26. An association between invasive breast cancer and familial idiopathic hyperparathyroidism: a case series and review of the literature.
    Pal SK; Blazer K; Weitzel J; Somlo G
    Breast Cancer Res Treat; 2009 May; 115(1):1-5. PubMed ID: 18500673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer.
    Nagore E; Montoro A; García-Casado Z; Botella-Estrada R; Insa A; Lluch A; López-Guerrero JA; Guillén C
    Melanoma Res; 2009 Aug; 19(4):211-4. PubMed ID: 19571771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
    Evans DG; Lalloo F; Ashcroft L; Shenton A; Clancy T; Baildam AD; Brain A; Hopwood P; Howell A
    Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2318-24. PubMed ID: 19661091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Moving genetics into clinical cancer care: examples from BRCA gene testing and telemedicine.
    Mackay J; Taylor A
    Breast; 2006 Dec; 15 Suppl 2():S65-70. PubMed ID: 17382866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast cancer and melanoma in the same pedigree.
    Seltzer MH; Leachman SA
    Dermatol Online J; 2008 Nov; 14(11):1. PubMed ID: 19094839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
    Forman AD; Hall MJ
    Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meeting the challenges of interpreting variants of unknown clinical significance in BRCA testing.
    Lattimore V; Currie M; Lintott C; Sullivan J; Robinson BA; Walker LC
    N Z Med J; 2015 Aug; 128(1419):56-61. PubMed ID: 26365847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA-1 in sporadic epithelial ovarian cancer: lessons learned from the genetics of hereditary disease.
    Cannistra SA
    Clin Cancer Res; 2007 Dec; 13(24):7225-7. PubMed ID: 18094398
    [No Abstract]   [Full Text] [Related]  

  • 34. Towards a dietary prevention of hereditary breast cancer.
    Kotsopoulos J; Narod SA
    Cancer Causes Control; 2005 Mar; 16(2):125-38. PubMed ID: 15868454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. European opposition to exclusive control over predictive breast cancer testing and the inherent implications for U.S. patent law and public policy: a case study of the Myriad Genetics' BRCA patent controversy.
    Paradise J
    Food Drug Law J; 2004; 59(1):133-54. PubMed ID: 15190928
    [No Abstract]   [Full Text] [Related]  

  • 36. A lesser evil: prophylactic mastectomy for women at high risk for breast cancer.
    Schover LR
    J Clin Oncol; 2008 Aug; 26(24):3918-9. PubMed ID: 18711178
    [No Abstract]   [Full Text] [Related]  

  • 37. Prophylactic surgery in the complex decision-making management of BRCA mutation carriers.
    Briasoulis E; Ziogas D; Fatouros M
    Ann Surg Oncol; 2008 Jun; 15(6):1788-90; author reply 1791-2. PubMed ID: 18197455
    [No Abstract]   [Full Text] [Related]  

  • 38. Rate of BRCA mutation in patients tested under NCCN genetic testing criteria.
    Beck AC; Yuan H; Liao J; Imperiale P; Shipley K; Erdahl LM; Sugg SL; Weigel RJ; Lizarraga IM
    Am J Surg; 2020 Jan; 219(1):145-149. PubMed ID: 31255259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic Testing for BRCA Mutations Today and Tomorrow-About the ABOUT Study.
    Narod S
    JAMA Oncol; 2015 Dec; 1(9):1225-6. PubMed ID: 26426337
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage.
    Yoshida K; Miki Y
    Cancer Sci; 2004 Nov; 95(11):866-71. PubMed ID: 15546503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.